Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma
Katie Maurer(Broad Institute), Caron A. Jacobson(Dana-Farber Cancer Institute), Michela Ansuinelli(Sapienza University of Rome), Jerome Ritz(Dana-Farber Cancer Institute), Brodie Miles(Children's Cancer Therapy Development Institute), Robert Redd(Harvard University), Mike Mattie, Roch Houot(Inserm), Isabella N. Grabski(Harvard University), Justin A. Budka(Gilead Sciences (United Kingdom)), Catherine J. Wu(Dana-Farber Cancer Institute), Yohei Arihara(Sapporo Medical University), Philippe Armand(Harvard University), Rafael A. Irizarry(Johns Hopkins University), Kenneth J. Livak(Broad Institute), Heather A. Jacene(Brigham and Women's Hospital), Haoxiang Lyu(Dana-Farber Cancer Institute), Wesley S. Lu(Harvard University), Shogo Miura(Dana-Farber Cancer Institute), Satyen H. Gohil(Broad Institute), Carol Reynolds(Harvard University), Shuqiang Li(Dana-Farber Cancer Institute), Mikaela M. McDonough(Dana-Farber Cancer Institute), Donna Neuberg(Otsuka (Japan))
Cited by 21
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
|Cell|2015|4.2k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k